Concurrent chemoradiation therapy with low-dose CDDP and UFT for glottic carcinomas: Evaluation using the sixth edition of the UICC TNM staging system

References

• International Union Against Cancer (UICC). TNM classification of malignant tumours, LH Sobin, Ch Wittekind. Wiley-Liss, New York 1997
   Google Scholar
• Burke LS, Greven KM, McGuirt WT, et al. Definitive radiotherapy for early glottic carcinoma: Prognostic factors and implications for treatment. Int J Radiat Oncol Biol Phys 1997; 38: 1001–6
   PubMed Web of Science ®Google Scholar
• Le QTX, Fu KK, Kroll S, et al. Influence of fraction size, total dose, and overall time on local control of T1-T2 glottic carcinoma. Int J Radiat Oncol Biol Phys 1997; 39: 115–26
   PubMed Web of Science ®Google Scholar
• Mendenhall WM, Amdur RJ, Morris CG, et al. T1-T2N0 squamous cell carcinoma of the glottic larynx treated with radiation therapy. J Clin Oncol 2001; 19: 4029–36
   PubMed Web of Science ®Google Scholar
• Al-Sarraf M. Treatment of locally advanced head and neck cancer: Historical and critical review. Cancer Control 2002; 9: 387–99
   PubMedGoogle Scholar
• Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003; 349: 2091–8
   PubMed Web of Science ®Google Scholar
• Kohno N, Kitahara S, Tamura E, et al. Concurrent chemoradiotherapy with low-dose cisplatin plus 5-fluorouracil for the treatment of patients with unresectable head and neck cancer. Oncology 2002; 63: 226–31
   PubMed Web of Science ®Google Scholar
• Jeremic B, Shibamoto Y, Stanisavljevic B, et al. Radiation therapy alone or with concurrent low-dose daily either cisplatin or carboplatin in locally advanced unresectable squamous cell carcinoma of the head and neck: A prospective randomized trial. Radiother Oncol 1997; 43: 29–37
   PubMed Web of Science ®Google Scholar
• Jeremic B, Shibamoto Y, Milicic B, et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: A prospective randomized trial. J Clin Oncol 2000; 18: 1458–64
   PubMed Web of Science ®Google Scholar
• Maguire PD, Meyerson MB, Neal CR, et al. Toxic cure: Hyperfractionated radiotherapy with concurrent cisplatin and fluorouracil for stage III and IVa head-and-neck cancer in the community. Int J Radiat Oncol Biol Phys 2004; 58: 698–704
   PubMed Web of Science ®Google Scholar
• Kumamoto Y, Masuda M, Kuratomi Y, et al. FAR. chemoradiotherapy improves laryngeal preservation rates in patients with T2N0 glottic carcinoma. Head Neck 2002; 24: 637–42
   PubMed Web of Science ®Google Scholar
• Murakami R, Nishimura R, Baba Y, et al. Prognostic factors of glottic carcinomas treated with radiation therapy: Value of the adjacent sign on radiological examinations in the sixth edition of the UICC TNM staging system. Int J Radiat Oncol Biol Phys 2005; 61: 471–75
   PubMed Web of Science ®Google Scholar
• International Union Against Cancer (UICC). TNM classification of malignant tumours, LH Sobin, Ch Wittekind. Wiley-Liss, New York 2002
   Google Scholar
• Murakami R, Baba Y, Furusawa M, et al. Early glottic squamous cell carcinoma: Predictive value of MR imaging for the rate of 5-year local control with radiation therapy. Acta Radiol 2000; 41: 38–44
   PubMed Web of Science ®Google Scholar
• Murakami R, Furusawa M, Baba Y, et al. Dynamic helical CT of T1 and T2 glottic carcinomas; predictive value for local control with radiation therapy. AJNR Am J Neuroradiol 2000; 21: 1320–6
   PubMed Web of Science ®Google Scholar
• Ferlito A, Silver CE, Howard DJ, et al. The role of partial laryngeal resection in current management of laryngeal cancer: A collective review. Acta Otolaryngol 2000; 120: 456–65
   PubMed Web of Science ®Google Scholar
• Schwachöfer JHM, Crooijmans RPMA, Hoogenhout J, et al. Effectiveness in inhibition of recovery of cell survival by cisplatin and carboplatin: Influence of treatment sequence. Int J Radiat Oncol Biol Phys 1991; 20: 1235–41
   PubMed Web of Science ®Google Scholar
• Scanlon KJ, Newman EM, Lu Y, Priest DG. Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc Natl Acad Sci USA 1986; 83: 8923–5
   PubMed Web of Science ®Google Scholar
• Shirasaka T, Shimamoto Y, Ohshimo H, et al. Metabolic basis of the synergistic antitumor activities of 5-fluorouracil and cisplatin in rodent tumor models in vivo. Cancer Chemother Pharmacol 1993; 32: 167–72
   PubMed Web of Science ®Google Scholar
• Iwase H, Shimada M, Nakamura M, et al. Concurrent chemoradiotherapy for locally advanced and metastatic esophageal cancer: Longterm results of a phase II study of UFT/CDDP with radiotherapy. Int J Clin Oncol 2003; 8: 305–11
   PubMedGoogle Scholar
• Fernández-Martos C, Aparicio J, Bosch C, et al. Preoperative uracil, tegafur, and concomitant radiotherapy in operable rectal cancer: A phase II multicenter study with 3 years’ follow-up. J Clin Oncol 2004; 22: 3016–22
   PubMed Web of Science ®Google Scholar
• Fujii S, Kitano S, Ikenaka K, et al. Effect of coadministration of uracil or cytosine on the anti-tumor activity of clinical doses of 1-(2-tetrahydrofuryl)-5-fluorouracil and level of 5-fluorouracil in rodents. Gann 1979; 70: 209–14
   PubMedGoogle Scholar
• Simpson D, Robertson AG, Lamont D. A comparison of radiotherapy and surgery as primary treatment in the management of T3N0M0 glottic tumours. J Laryngol Otol 1993; 107: 912–5
   PubMed Web of Science ®Google Scholar
• Mendenhall WM, Parsons JT, Mancuso AA, et al. Definitive radiotherapy for T3 squamous cell carcinoma of the glottic larynx. J Clin Oncol 1997; 15: 2394–402
   PubMed Web of Science ®Google Scholar
• Horiot JC, Bontemps P, van den Bogaert W, et al. Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: Results of the EORTC 22851 randomized trial. Radiother Oncol 1997; 44: 111–21
   PubMed Web of Science ®Google Scholar
• Fu KK, Pajak TF, Trotti A, et al. A Radiation Therapy Oncology Group (RTOG) Phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: First report of RTOG 9003. Int J Radiat Oncol Biol Phys 2000; 48: 7–16
   PubMed Web of Science ®Google Scholar